DL

Dr. Lin Yang

Founder, Chairman and CEO

PersonGen BioTherapeutics

Therapeutic Areas

PersonGen BioTherapeutics Pipeline

DrugIndicationPhase
TAA06 injectionT-cell malignancies (specific type not specified)Phase 1
LV009 injectionRelapsed/Refractory CD19-positive hematologic malignanciesClinical Trial (phase not specified)
CD7-CAR-T programT-cell malignanciesNot specified